Download - Biopharming Training
-
8/2/2019 Biopharming Training
1/97
-
8/2/2019 Biopharming Training
2/97
Concept of Biopharming
Knowledge on structure and function of cellularmacromolecules
Isolation and characterization of genes, cloning a
gene and studying its structure and expression throughrecombinant DNA (rDNA) technology
rDNA technology in biological research
rDNA technology in pharmaceutical industry
-
8/2/2019 Biopharming Training
3/97
The concept of biopharming is not new.
Common medicines, such as codeine, morphine, bulk laxatives, and the anticancerdrugs such as taxol and vincristine have long been purified from plants.
But biopharmings great promise lies in using genetic modification i.e., techniques tomake wild (nontransformed) plants to do drastic new things.
Biopharming offers tremendous advantages over traditional methods for producingpharmaceuticals.
Great potential for reducing the costs of production.
The energy for product synthesis comes from the sun, and the primary raw materialsare water and carbon dioxide.
To expand production, it is much easier to plant a few additional hectares than tobuild a new bricks-and-mortar manufacturing facility.
Vaccines produced in this way will be designed to be heat-stable so that norefrigeration chain from manufacturer to patient will be required. This would have agreat application in developing countries, especially in the tropics and throughoutAsia and Africa.
-
8/2/2019 Biopharming Training
4/97
Use of Microbes Earlier days microbes were well exploited among which bacteria are
highly exploited.
Eg. human growth hormone and insulin.
Prior to the advent of genetic engineering, human growth hormonewas produced from pituitary glands removed from cadavers. Itresulted in recipients contracting CreutzfeldJakob syndrome.
The recombinant approach resulted in unlimited supplies of safematerial. This safety aspect has been extended to various clottingfactors that were originally isolated from blood but now carry the riskof HIV infection.
As the methods for cloning genes became more and more
sophisticated, an increasing number of lymphokines and cytokineswere identified and significant amounts of them produced for the firsttime.
-
8/2/2019 Biopharming Training
5/97
Use of microbes for production of recombinant therapeutic proteins hasseveral problems
The foreign gene may contain sequences that act astermination signals.
The codon usage of the gene may not be ideal for translation
in bacterial system (Codon bias).
Lack of post translational modification and correct folding ofthe human recombinant proteins in microbial system.
Degradation of recombinant proteins since it is somewayrecognized as foreign protein in bacteria.
-
8/2/2019 Biopharming Training
6/97
-
8/2/2019 Biopharming Training
7/97
Selective examples of recombinant proteins and their applications
-
8/2/2019 Biopharming Training
8/97
Transgenic animals and plants as Bioreactors
Recombinant-protein synthesis in animal cells has a number ofadvantages over microbial expression systems, the most importantof which is the authentic post-translational modifications that areperformed in animal cells.
However, large scale culture of animal cells is expensive.
The production of growth hormone in the serum of transgenic miceprovided the first evidence that recombinant proteins could beproduced, continuously, in the body fluids of animals.
Secretion of recombinant proteins in mouse milk was reported. This
was achieved by joining the transgene to a mammary-specificpromoter, such as that from the casein gene.
The first proteins produced in this way were sheep -lactoglobulinand human tissue-plasminogen activator (tPA).
-
8/2/2019 Biopharming Training
9/97
Selective examples of therapeutic compounds produced usinganimals as bioreactors
-
8/2/2019 Biopharming Training
10/97
Plants as bioreactors
Plants are a useful alternative to animals for recombinant-
protein production because they are inexpensive
Therefore, there is much interest in using plants as productionsystems for the synthesis of recombinant proteins and otherspeciality chemicals.
There is some concern that therapeutic molecules producedin animal expression systems could be contaminated withsmall quantities of endogenous viruses or prions, a risk factorthat is absent from plants.
Furthermore, plants carry out very similar post-translationalmodification reactions to animal cells, with only minordifferences in glycosylation patterns. Thus plants are quitesuitable for the production of recombinant human proteins fortherapeutic use.
-
8/2/2019 Biopharming Training
11/97
Selective examples of recombinant human therapeutic proteinsexpressed in plants
-
8/2/2019 Biopharming Training
12/97
The first such report was the expression of human growth hormone,as a fusion with the AgrobacteriumNopaline synthase enzyme, intransgenic tobacco and sunflower.
Tobacco has been the most frequently used host for recombinant-protein expression although edible crops, such as rice, are nowbecoming popular, since recombinant proteins produced in suchcrops could in principle be administered orally without purification.
The expression of human antibodies in plants has particular
relevance in this context, because the consumption of plant materialcontaining recombinant antibodies could provide passive immunity(i.e. immunity brought about without stimulating the host immunesystem).
Antibody production in plants was first demonstrated by Hiatt and
During team, who expressed full-size immunoglobulins in tobaccoleaves. Since then, many different types of antibody have beenexpressed in plants, predominantly tobacco, including full-sizeimmunoglobulins, Fab fragments and single-chain Fv fragments(scFvs).
-
8/2/2019 Biopharming Training
13/97
A fully humanized antibody against herpes simplex virus-2 (HSV-2) has been expressed in soybean.
Even secretory IgA (sIgA) antibodies, which have fourseparate polypeptide components, have beensuccessfully expressed in transgenic tobacco plants.
Plants producing recombinant sIgA against the oralpathogen Streptococcus mutanshave been generated,and these plant-derived antibodies (plantibodies) haverecently been commercially produced as the drug
CaroRxTM, marketed by Planet Biotechnology Inc.
-
8/2/2019 Biopharming Training
14/97
Isolation of gene sequence
Codon optimization andConstruction of Recombinant vector
Transformation
Plant/Animal/Microbes
High throughput
Expression ofCloned genes
Separation and purificationof medicinal protein
-
8/2/2019 Biopharming Training
15/97
-
8/2/2019 Biopharming Training
16/97
Microbial production of Pharmaceutical compounds
Human disorders due to the absence or malfunction of a protein
normally synthesized in the body.
Treatment by supplying the patient with the correct version of theprotein, but for this to be possible the relevant protein must beavailable in relatively large amounts.
Obtaining sufficient quantities will be a major problem unlessdonated blood can be used as the source in some cases.
Animal proteins are used whenever these are effective, but thereare not many disorders that can be treated with animal proteins andthere is always the possibility of side effects such as an allergenicresponse.
-
8/2/2019 Biopharming Training
17/97
Microbial production of Insulin
Insulin, synthesized by the -cells of the islets of Langerhans in the
pancreas, controls the level of glucose in the blood.
Deficiency leads to Diabetes mellitus.
Treatment with insulin injections and supplementing the limited amount ofhormone synthesized by the patients pancreas.
Traditionally obtained from the pancreas of pigs and cows slaughtered formeat production.
Although animal insulin is generally satisfactory, problems may arise in itsuse to treat human diabetes.
slight differences between the animal and human proteins may lead to sideeffects in some patients.
the purification procedures are difficult and potentially dangerouscontaminants can not always be completely removed
l Z A l cZ B gene
-
8/2/2019 Biopharming Training
18/97
LacpromoterlacZ A gene
LacpromoterlacZ B gene
Vector carrying the
Artificial A and B genes
met
galactosidasesegment
A chain
galactosidasesegment
met
B chain
AB
TransformedE. colisynthesize
A and B fusion proteins
Purification of A and B chains
Attach by disulphide bridges
Synthesis of insulin protein
Cyanogen bromide
Cleaved fusion proteins Cleaved fusion proteins
BA
-
8/2/2019 Biopharming Training
19/97
Synthesis of human growth hormone in E. coli
Somatostatin and somatotropin
Somatostatin - somatotropin release-inhibiting factor (SRIF) expressed in the central and peripheral nervous systems, the gut, and other
organs also inhibit the release of thyroid-stimulating hormone; prolactin; insulin; and
glucagon besides acting as a neurotransmitter and neuromodulator.
Agromegaly (uncontrolled bone growth) and dwarfism.
Somatostatin was the first human protein to be synthesized in E. coli.
Somatostatin - very short protein, only 14 amino acids in length, it wasideally suited for artificial gene synthesis.
Strategy - insertion of the artificial gene into a lacZ reading frame of thepBR 322 vector, synthesis of a fusion protein and cleavage with cyanogensbromide.
-
8/2/2019 Biopharming Training
20/97
Lacpromoter
lacZ Artificial somatostatin gene
galactosidase
segment
met
Somatostatin fusion
protein
Transformation intoE. coli
Cyanogen bromide
Cleaved somatostatin
Production of recombinant somatostatin
-
8/2/2019 Biopharming Training
21/97
Somatotropin
Somatotropin -191 amino acids in length, equivalent to almost 600 bp,
Combination of artificial gene synthesis and cDNA cloning was used toobtain a Somatotropin-producing E. colistrain.
mRNA was obtained from the pituitarygland and a cDNA library wasprepared.
The Somatotropin cDNA turned out to have a unique site for the restrictionendonucleases HaeIII, which cuts the gene into two segments.
The longer segment, consisting of codons 24 to 191, was retained for use inconstruction of the recombinant plasmid.
The smaller segment was replaced by an artificial DNA molecule thatreproduced the start of the Somatotropin gene and provided the correctsignals for translation in E. coli.
The modified gene was then ligated into an expression vector carrying thelacpromoter.
-
8/2/2019 Biopharming Training
22/97
Production of recombinant somatotropin cDNA fragmentCodons 0 24 191
HaeIII
0 24 24 191
Discard Retain
Synthetic leadersequence
Expression of somatotropin
LacpromoterlacZ somatotropin gene
E. colitransformationSomatotropin is
synthesized
-
8/2/2019 Biopharming Training
23/97
Recombinant Factor VIII
Central role in blood clotting.
Recombinant pharmaceutical protein produced in eukaryotic cells
Haemophilia
Treatment - injection of purified Factor VIII protein, obtained from humanblood provided by donors.
Purification is a complex procedure and the treatment is very expensive
Difficult to remove the virus particles that are present in the blood. Hepatitis and AIDS can and have been passed on to haemophiliacs via
Factor VIII injections.
Recombinant factor VIII, free from contamination problems, would besignificant achievement for biotechnology.
-
8/2/2019 Biopharming Training
24/97
The factor VIII gene is very large,
Over 186 kb in length, and is split into 26 exons and 25 introns.
The mRNA codes for a large polypeptide (2351 amino acids) whichundergoes a complex series of post-translational processing events,eventually resulting in a dimeric protein consisting of a largesubunit, derived from the upstream region of the initial polypeptideand a small subunit from the downstream segment.
The two subunit contain a total of 17 disulphide bonds and a numberof glycosylated sites.
It is not possible to synthesize an active version in E. coli.
Most attempts made on mammalian cells.
-
8/2/2019 Biopharming Training
25/97
First, entire cDNA was cloned in hamster cells, but yields of protein weredisappointingly low.
Because of the failure in post-translational events, (do not convert theentire initial product into an active form limiting the overall yield).
As an alternative, two separate fragments from the cDNA were used,one fragment coding for the large subunit polypeptide, the second forthe small subunit.
Each cDNA fragment was ligated into an expression vector,downstream of the Ag promoter(a hybrid between the chicken -actinand rabbit -globin sequences) and upstream of a polyadenylationsignal from SV40 virus.
The plasmid was introduced into a hamster cell line and recombinant
protein obtained.
The yields were over ten times greater than those from cells containingthe complete cDNA and the resulting factor VIII protein wasindistinguishable in terms of function from the native form
-
8/2/2019 Biopharming Training
26/97
-
8/2/2019 Biopharming Training
27/97
Tissue Plasminogen Activator (tPA)
naturally occurring protease enzyme, helps to dissolveblood clots inside a blood vessel
Boon for patients suffer from thrombosis
1st pharmaceutical product to be produced bymammalian cell culture
Majority of the natural deaths due to blockade ofcerebral/coronary artery (thrombus)
-
8/2/2019 Biopharming Training
28/97
Production of recombinant tPASynthesize cDNA molecule for tPA
Attached to synthetic plasmid
Introduced into mammalian cells
Cultured and tPA producing cells were selected by using methotrexate to the medium
tPA producing cells were transferred to fermenter
tPA secreted into culture medium is isolated for therapeutic purpose
-
8/2/2019 Biopharming Training
29/97
Synthesis of other recombinant human proteins
Interferon and interleukins - cancer therapy. Serum albumin, are more easily obtained, but are
needed in such large quantities that production inmicroorganisms is still a more attractive option.
Erythropoietin hormone synthesized by the kidneystimulate the stem cells of bone marrow to producemature erythrocytes
-
8/2/2019 Biopharming Training
30/97
Interferon
Antiviral substance
First line of defense against viral attacks
Glycoprotein in nature
Containing a group of > 20 substances with
mol. Wt of 20000 - 30000 daltons
Interferon
Interferon
Interferon
-
8/2/2019 Biopharming Training
31/97
rDNA derived therapeutic agents (approved by FDA) with tradenames and their applications in humans
rDNA product Trade name Application/uses
Insulin Humulin Diabetes
Growth hormone Protropin/Humatrope Pituitary dwarfism
Hepatitis Bvaccine Recombinax HB/Engerix B Hepatitis B
Tissue
Plasminogen
Activator
(tPA)
Activase Myocardial infarction
Factor VIII Kogenate/Recombinate Hemophilia
DNase Pulmozyme Cystic fibrosis
Erythropoietin Epogen Severe anaemia with kidney
damage
-
8/2/2019 Biopharming Training
32/97
Some otherrDNA derived therapeutic agents approvedby USFDA
rDNA product Application/uses
Coagulation factor VIII Hemophilia A
Coagulation factor IX Christmas disease (Hemophilia B)
Interferon Leukemia
Interferon Multiple sclerosis
Interferon Chronic granulomatous disease
Interleukin 2 Renal cell carcinoma (Kidney cancer)
Interleukin 10 Thrombocytopenia (few platelets inblood)
-
8/2/2019 Biopharming Training
33/97
Restriction endonucleases
> 500 different restriction endonucleases
Synthesized by a wide range of microorganisms and for eachorganism, a detailed fermentation protocol, has to bedeveloped and optimized
To avoid having to maintain a large number of differentmicroorganisms, stock a very wide range of mediumcomponents, design several different fermenters and spendan inordinate amount of time developing optimal growthconditions for a large number of different organisms,researchers often clone restriction enzyme gene into E.coli.
Because it is easy to standardize the conditions and E. colicells grow rapidly to high cell densities and can be engineeredto significantly over express the target restriction enzymes.
-
8/2/2019 Biopharming Training
34/97
However, host organism is dramatically affected
by the production or presence of a heterologousprotein.
Over expression of heterologous protein maydrain the host organism of important metabolic
resources and this may affect its growth orsometimes it may be lethal to the host.
Eg. There is a possibility to digest the host DNA
by the heterologous restriction enzyme unless aprotection mechanism is present.
-
8/2/2019 Biopharming Training
35/97
Microbial system has also been used to synthesizeseveral industrially important
low molecular weight molecules L-ascorbic acid (Vitamin C)
indigo
amino acids
antibiotics and
high molecular weight molecules biopolymers (Xanthan gum)
melanin
rubber
polyhydroxyalkanoates etc.
-
8/2/2019 Biopharming Training
36/97
-
8/2/2019 Biopharming Training
37/97
Transgenic animals
Gene transfer to animal cells has been practiced for thepast 40 years.
Techniques are available for the introduction of DNA intomany different cell types
Animal cells - advantageous for the production ofrecombinant animal proteins (authentic post-translational modifications) that are not carried out by
bacterial cells and fungi.Cell cultures - commercial scale to synthesize products
-
8/2/2019 Biopharming Training
38/97
Intense research - efficient vector systems andtransformation methods for animal cells.
Baculovirus expression system - in insects.
More recently, introduction of DNA into animal cells in
vivoto treat disease (in vivogene therapy).
Viral gene-delivery vectors are favoured for therapeuticapplications because of their efficiency, but safetyconcerns have prompted research into alternative DNA-mediated transfer procedures.
G
-
8/2/2019 Biopharming Training
39/97
Gene-transfer strategies
(1) Direct DNA transfer - the physical introduction of foreign
DNA directly into the cell. microinjection - in cultured cells bombardment with tiny DNA-coated metal particles - for
cells in vivo.
(2) Transfection - chemical and physical, which can be
used to persuade cells to take up DNA from theirsurroundings.
(3) Transduction: Packaging the DNA inside an animalvirus
Transformation can be transient or stable, depending onhow long the foreign DNA persists in the cell.
-
8/2/2019 Biopharming Training
40/97
Proteins with therapeutic and industrial value have been produce(not commercialized) in the milk of transgenic animals
Protein Animal Use
Antithrombin III Goat Reduce the amount of blood needed in somesurgeries
Factor VIII and IX Goat, Pig,Sheep
Treatment of Hemophila
CFTR (Cystic
FibrosisTransmembrane
conductance
regulator)
Sheep Treatment of Cystic Fibrosis
Lactoferrin Cow Natural antibiotic and used in coronary surgery
Alpha 1 anti trypsin Sheep Treatment of Cystic Fibrosis and emphysema
Lysostaphin Cow Antibacterial compound that prevents mastitis incows
Spider silk protein Goat Production of ultra strong and light weight
industrial materials
-
8/2/2019 Biopharming Training
41/97
-
8/2/2019 Biopharming Training
42/97
-
8/2/2019 Biopharming Training
43/97
Transgenic animals:
Animals which have been genetically engineered tocontain one or more genes from an exogenoussource.
Transgenes are integrated into the genome.
Transgenes can be transmitted throughgermlineto progeny.
First transgenic animal produced = Founder Animal
-
8/2/2019 Biopharming Training
44/97
Mouse animal of choice for transgenic expt.
Easily handled and researcher friendly
Transgenic mice contributed Understanding of
Mol. Biol
Genetics Immunology
Cancer studies
Animal models for human genetic diseases
-
8/2/2019 Biopharming Training
45/97
Methods for introducing foreign gene/Transgenic mice production
Retroviral vector
Microinjection
ES cell method
-
8/2/2019 Biopharming Training
46/97
Retroviral vector
Transfer small pieces of DNA (8kb)
Not suitable for large DNA
Risk of losing regulatory sequences
Risk of retroviral contamination
A commercial product is to be synthesizedby the transgenic organism or thetransgenic organism to be used as food, itis absolutely necessary that there be noretroviral contamination.
Retroviral vector method
-
8/2/2019 Biopharming Training
47/97
Cleavage stage embryos (eight-cell stage)
infected with defective
retrovirus carrying a transgeneImplanted females (foster mothers)
Transgenic pups
Matings are carried out to determine which pups have the
transgene in their germ line cells.
Transgenic lines can be established from these foundertransgenic animals
-
8/2/2019 Biopharming Training
48/97
Microinjection method
-
8/2/2019 Biopharming Training
49/97
Microinjection method
(Super ovulated female) Young virgin female mice (4-5 weeks)FSH (pregnant mares serum)
2 days latter human chorionic gonadotropin
Produce 30 35 eggs
Mated with males and sacrificed on the following day
Fert. Eggs removed from the fallopian tubesmicroinjection needle
DNA inserted into male pronucleus of fert. Eggs
Eggs with transgene kept overnight in incubator to develop 2 cell stage
Implanted in foster mother (Pseudomouse pregnant female mouse mated with avasectomised male)
3 weeks after implantation
Transgenic pups
PCR/Southern blot hybridisation
-
8/2/2019 Biopharming Training
50/97
-
8/2/2019 Biopharming Training
51/97
-
8/2/2019 Biopharming Training
52/97
-
8/2/2019 Biopharming Training
53/97
Limitations of microinjection method
Low efficiency (3 5 % success rate)
Foreign DNA randomly integrates into the host genome
Many pieces of DNA get incorporated at single site
Transgene may not be expressed / over expressed /under expressed and affect normal physiology
Time consuming
Costly
Labour intensive
E b i St C ll M th d
-
8/2/2019 Biopharming Training
54/97
Embryonic Stem Cell Method Introduction of foreign DNA into ES cell by
electroporation/micro injection
Cells from the blastocyst stage of a developing mouseembryo can proliferate in cell culture and have thecapability of differentiating into all other cell types-including germ line cells-after they are reintroduced into
another blastocyst embryo (Pluripotency).
Pluripotency in the broad sense refers to "having morethan one potential outcome".
Pluripotent stem cells can give rise to any fetal or adultcell type.
Embryonic stem cells (ES cells) are harvested from theinner cell mass (ICM) of mouse blastocysts.
-
8/2/2019 Biopharming Training
55/97
1. Make your DNA Using recombinant DNA methods, DNA containing the structural gene,
vector DNA, Promoter and enhancer sequences to enable the gene tobe expressed by host cells
2. Transform ES cells in culture Expose the cultured cells to the DNA so that some will incorporate it.
3. Inject these cells into the inner cell mass (ICM) of mouse blastocysts
4. Embryo transfer(Implantation) Prepare a pseudopregnant mouse (to make uterus receptive). Transfer the embryos into her uterus. develop into healthy pups (no more than one-third will).
5. Test her offspring
Remove a small piece of tissue from the tail and examine its DNA for thedesired gene.
6. Establish a transgenic strain Mate two heterozygous mice and screen their offspring for the 1:4 that will
be homozygous for the transgene.
Mating these will found the transgenic strain.
-
8/2/2019 Biopharming Training
56/97
-
8/2/2019 Biopharming Training
57/97
-
8/2/2019 Biopharming Training
58/97
-
8/2/2019 Biopharming Training
59/97
-
8/2/2019 Biopharming Training
60/97
-
8/2/2019 Biopharming Training
61/97
Transgenesis in large animals
More difficult than with miceLess number of eggsTechnical difficulties in handlingLong gestational period
Early expts. not satisfactory
Transgenic sheep overproducing growth hormone susceptible toinfection, infertile and tend to die at early stage
Due to ineffective control of gene regulation
Resistance to diseases, enhancing the milk production, production ofcommercial and pharmaceutical compounds
T i ttl
-
8/2/2019 Biopharming Training
62/97
Transgenic cattle Mammary gland of the dairy cattle- ideal bioreactor
Transgenic cow over expressed K - casein transgene milk withhigher content of casein
Lactase transgene lactose free milk lactose intolerant people
Resistance to viral, bacterial and parasitic diseases
Attempts inherited immunological protection through transgenesis
Introduction of genes that code for heavy and light chains ofmonoclonal antibodies has met with some success
In vivoimmunization ideal for disease protection, which involvesthe insertion of a transgene for an antibody that specifically binds toan antigen
-
8/2/2019 Biopharming Training
63/97
Mature oozytes are collected from cows and fertilized withsemen collected from a bull in vitro.
Fertilized oozytes are centrifuged to settle the yolk at onepole of the oozytes
Foreign gene is microinjected into male pronucleus in theoozytes
Oozytes grown in vitrotill blastocyst stage
Implanted in uterus of foster mother
T i h
-
8/2/2019 Biopharming Training
64/97
Transgenic sheep
Mostly involve development of mammary glands asbioreactors for the production of proteins forpharmaceutical use. Eg. 1-antitrypsin, Factor IX
1-antitrypsin is fused with -lactoglobin promoter
microinjected into male pronucleus of fertilized egg.
1-35 g of 1-antitrypsin per litre of milk
Gene for factor IX
Isolated and purified from milk to treat haemophilia
Transgenic sheep
-
8/2/2019 Biopharming Training
65/97
Transgenic sheep
Keratin wool protein, highly cross linked disulfide bridges
Cysteine is required in large quantities - quality wool
Cysteine supply inadequate
Microbes harbouring in the rumen utilize it and release in the form ofsulfide
Transgenic sheep containing bacterial genes for synthesis ofcysteine
Two enzymes , synthesized by the transgenes trap the H2S andliberate in the intestine to produce the cysteine
Good supply of cysteine to the sheep improves the quality andquantity of wool
-
8/2/2019 Biopharming Training
66/97
Transgenic goats
Transgenic goats with tPA gene producestissue Plasminogen activator in milk
Transgenic pigs
-
8/2/2019 Biopharming Training
67/97
Transgenic pigs
Gene for Factor VIII introduced into zygote of pig by microinjection
Zygote implanted in uterus of a sow
Factor VIII in milk
For haemophilia treatment
-
8/2/2019 Biopharming Training
68/97
Human haemoglobins (globulin gene)
Human haemoglobins can be separated from pig haemoglobins byanalytical techniques
Haemoglobin O2 carrying protein of RBC can be used as a substitute inblood transfusion expts.
Haemoglobin can be stored for longer time than whole blood
No problem of contamination compared to whole blood
Free haemoglobins can not transport O2 as likehaemoglobins of RBC
Naked haemoglobin is easily degraded and breakdown products causedamage to kidney
Contamination by pig viruses and other compounds cause allergic reactions
Xenotransplantation
-
8/2/2019 Biopharming Training
69/97
Xenotransplantation
Transplantation of animal organs in human system
Human organs such as liver, pancreas, kidney and lungs greatdemand for transplantation surgery
Shortage can be overcome by developing them in mammal
Pig favourite animal for harvesting human organs
But human body produced antibodies against pig organs reject thetransplantsHyperacute rejection
Imutran Company (USA) produced transgenic pig (Astrid) bymicroinjecting genes for human immune system into malepronucleus of the zygote
Transgenic rabbits
-
8/2/2019 Biopharming Training
70/97
Transgenic rabbits
Interleukin-2 gene along with -casein promoter
Interleukin-2 is produced in milk
To treat cancers
Transgenic rabbits with human growth hormone genegrow faster and produce more meat with in short
duration
Transgenic chickens
-
8/2/2019 Biopharming Training
71/97
Transgenic chickens
Complicated
Fertilization several sperms enter the ovum instead of one(contrast to mammals)
Identification of male pronuclei that will fuse with female pronuclei isquite difficult
ES cells have not been identified in chickens The blastoderm cells can be removed from a donor chicken and are
transfected with transgenes Modified blastoderm cells reintroduced into subgerminal space of
irradiated blastoderm of freshly laid eggs Transgenic lines are produced Transgenesis for low fat and cholesterol, high protein containing
eggs Resistance to viral and bacterial diseases , Production of
pharmaceutical proteins Transgenic chickens resistant to Avian Leukosis virus (ALV)
Transgenic animals as bioreactors for the productionf th ti t i
-
8/2/2019 Biopharming Training
72/97
of therapeutic proteins
Transgenic
animalProtein product Biological importance
Cow Lactoferrin To overcome iron deficiency anaemias and alsoposssses antibacterial activity
Cow Interferon Resistance against viral infections
Sheep 1 antitrypsin Treatment of emphysema in lungs(Promotes gas exchange in lungs)
Goat CFTR To treat CF (promotes transport of ions)
Goat tPA To treat myocardial infarctions (to dissolve blood clots)
Goat Antithrombin III Regulates blood clotting
Rabbits glucosidase To treat Pompes disease (A genetic disorder
characterized by block in glycogen degradation)Mouse Urokinase to dissolve blood clots
Mouse Immunoglobulins Nhances immunity
-
8/2/2019 Biopharming Training
73/97
Conventional vaccines Purified antigen vaccines Recombinant vaccines
Vaccines
Live vaccines Inactivated pathogen Recombinant proteins/Sub unit vaccines
DNA Vaccines
Whole protein molecule Polypeptide
Con entional accines
-
8/2/2019 Biopharming Training
74/97
Conventional vaccines
consist of whole pathogenic organisms (bacterial / viral vaccines), which
may be either killed or live (attenuated) (live vaccines) (most viral vaccines)
Highly effective and easy to produce at low cost.
Limitations:
In many cases live vaccine have to be used, killed pathogen vaccines are
ineffective
Live vaccines are generally based on cultured animal cells and expensive tissueculture set up is essential
Live vaccines are heat labile
Risk of disease development due to occasional presence of active virus particle orreversion to virulence
Purified antigen vaccines
-
8/2/2019 Biopharming Training
75/97
Based on purified antigens isolated from concerned pathogens
Since they do not contain the organism, risk of pathogenicity isavoided
Limitations:
Cost is higher due to steps involved in purification and vaccinepreparation
Many of isolated antigens are poorly immunogenic
Successful examples of such vaccines are mostly from bacteria
Eg. Vaccines based on polysaccharide antigens from bacterial cell wallcapsules of Neisseria meningitisand Streptococcus pneumoniae
Many bacteria produce exotoxins, which are highly immunogenic. Butthese toxins produce toxic effects and it may decrease with storage dueto heat and chemicals. Fortunately most exotoxins that have lost theirtoxicity retain their immunogenecity; they are called toxoids and areeffectively used as effective vaccines.
Eg. Toxoids of pathogens causing tetanus, diphtheria etc.
-
8/2/2019 Biopharming Training
76/97
Recombinant vaccines
Contains either a protein or a gene encoding aprotein of a pathogen origin that is immunogenic
and critical to pathogen function; the vaccine isproduced using recombinant DNA technology.
Vaccines based on recombinant proteins are
called as sub unit vaccines.
-
8/2/2019 Biopharming Training
77/97
Steps involved:
Identification of protein that is immunogenic andcritical for the pathogen
Gene encoding for the protein is identifiedisolated
Gene is inserted into a expression vector andintroduced in to suitable host where it produceslarge quantity
Protein isolated and purified from the host cells. It is used for the preparation of vaccine.
Comparison of different biological systems for
th ti t i d ti
-
8/2/2019 Biopharming Training
78/97
therapeutic protein production
Production of therapeutic proteins in plants
-
8/2/2019 Biopharming Training
79/97
Production of therapeutic proteins in plants
Until recently pharmaceuticals used for treatment of diseases
largely based on the production of relatively small organisms. Molecules synthesis by microbes or by organic chemistry
antibiotics, analgescis, hormones and others
Proteins are large molecules composed of long chains of subunits
called amino acids. Structure and functionality of given protein is determined by its
sequence of amino acids, which, in turn, determines its three
dimensional confrontation / structure.
Internal bonds (S and H bonds) among the amino acids give theproteins its final shape and form.
-
8/2/2019 Biopharming Training
80/97
Complex proteins undergo further processing such as
phosphorylation and glycosolation, which modify proteins functions.
Information stored in DNA directs the protein synthesizing
machinery of the cell to produce specific protein required for its
structure, function and metabolism.
Since proteins play critical roles in cell biology, they have many
therapeutic uses in preventing and curing diseases and disorders.
Short peptide chains can be synthesized chemically whereas large
peptides in living cells.
DNA that encodes the instructions for producing desired proteins is
inserted into cells and as the cells grow they synthesize the proteinsand subsequently they are harvested and purified.
-
8/2/2019 Biopharming Training
81/97
Recently transgenic plant expression systems were well
developed.
Use of plants as a means of lower cost of production and
easier expansion of larger volume of production than cell
culture systems.
However 50% of total cost of production goes forextraction and purfication.
Plant system able to produce complex proteins with
some extent of post translational modifications.
Therapeutic proteins
-
8/2/2019 Biopharming Training
82/97
p p
Antibodies
Passive immunization an immune response that results from injecting
another organisms antibodies into organism that is being challenged
by the pathogen
Passive immunization using MAB are largest category of biotech derived
drugs.
In passive immunization, rather than injecting an antigen and inducingthe body to produce antibodies against it, an antibody targetted
towards a specific antigen is administered as a therapeutic.
Eg. Multiple doses of Herceptin against breast cancer
Antibody therapes are available for lymphoma, rheumatoid arthritis,
respiratory synchytial virus
Clinical trials are underway.
Antibodies produced from transgenic plants are
-
8/2/2019 Biopharming Training
83/97
p g pused for the treatment of
Dental caries Rheumatoid arthritis Cholera E. colidiarrohea
Malaria Certain cancers HIV Norwalk virus Rhino virus
Influenza Hepatitis B Herpes simplex virus
Vaccines
-
8/2/2019 Biopharming Training
84/97
Protein antigens from various pathogens have beenexpressed in plants and used to produce immune
responses resulting in protection against diseases. Plant derived vaccines against Vibrio cholerae,
enterotoxigenic E. coli, Hepatitis B virus, Norwalk virus,rabies virus, human cytomegalo virus, respiratory
synchytial virus Insulin expression in plants produceda vaccine useful for
protection against insulin dependent auto immuneMellitus diabetes
Antigen specific to an individual patient tumor areexpressed in tobacco, harvested, purified andadministered to the patient.This entire process will takeplace as little as 4 weeks compared to 9 months for the
same process in mammalian cell culture.
-
8/2/2019 Biopharming Training
85/97
Plant derived antigens purified and usedas injectable vaccines.
Oral delivery of these vaccines with infoods also successful.
Edible vaccines
-
8/2/2019 Biopharming Training
86/97
Edible vaccines
Low cost delivery mechanism for immunisation
No need for injection, sterile needles, and refrigeration Edible vaccines successfully immunized test animals against
enterotoxigenic E. coli, V. cholerae, hepattitis B, norwalk virus rabies
virus etc.
Concentration of vaccine protein in edible vaccine is relatively low.
Research is underway to increase them in targeted sites. Eg.
Potato, Tomato, banana and carrot
Potato cooking inactivate the vaccine.
Tomato and banana short storage lifeCarrot few storage problems, can be eaten raw. (hepatitis B vaccine)
Ch ll
-
8/2/2019 Biopharming Training
87/97
Challenges:
Standardization of expression
Dosage level and immune responses
Distributed through health service channels
Decrease the cost of immunisation indeveloping countries
Eg. Golden rice program
P ibl l l f i d t i l d
-
8/2/2019 Biopharming Training
88/97
Possible molecular farming products include:
1) Primary Products 2) Derived Products
Monoclonal Antibodies,Immunogloblulin (Ig) fragments-
Fabs, scFv (Passive immunity)
Bio-plastics - PHAs(polyhydroxyalkanoates, chemically
related to polyesters).
Antigens (vaccines) (Active
immunity)
Structural: proteins, peptides,
hormones, (interleukins,
interferons and colony stimulating
factors)
Enzymes: food, feed, industrial,
therapeutic, diagnostic, cosmetic
Nutraceuticals:
Macro: Carbohydrates, Fats
Micro: Vitamins, co-factors, minerals,
Phytochemicals: carotenoids (beta-
carotene, lycopene, lutein), flavonoids
(quercetin, kaempferol, allicin),
isoflavones (phytoestrogens -
genistein and daidzein),
isothiocyanates (glucosinolates,
indoles, and sulforaphane), phenolics(reservatrol, catechin), tannins
Anti-disease therapeutics: Factor
VII,
Non-nutrient phytochemicals: fragrances,
flavors
Enzyme inhibitors Fibres: polymers, lignins
Th G ld Ri St
-
8/2/2019 Biopharming Training
89/97
The Golden Rice Story
Vitamin A deficiency is a major health problem
Causes blindness
Influences severity of diarrhea, measles
>100 million children suffer from the problem
For many countries, the infrastructure doesnt exist
to deliver vitamin pills
Improved vitamin A content in widely consumed crops
an attractive alternative
Carotene Pathway Problem in Plants
-
8/2/2019 Biopharming Training
90/97
-Carotene Pathway Problem in PlantsIPP
Geranylgeranyl diphosphate
Phytoene
Lycopene
-carotene(vitamin A precursor)
Phytoene synthase
Phytoene desaturase
Lycopene-beta-cyclase
-carotene desaturase
Problem:
Rice lacks
these enzymes
Normal
Vitamin A
Deficient
Rice
The Golden Rice Solution
-
8/2/2019 Biopharming Training
91/97
IPP
Geranylgeranyl diphosphate
Phytoene
Lycopene
-carotene(vitamin A precursor)
Phytoene synthase
Phytoene desaturase
Lycopene-beta-cyclase
-carotene desaturase
Daffodil gene
Single bacterial gene;
performs both functions
Daffodil gene
-Carotene Pathway Genes Added
Vitamin A
Pathway
is complete
and functional
Golden
Rice
I t d i th G
-
8/2/2019 Biopharming Training
92/97
Introducing the Gene
or
Developing Transgenics
Steps
1. Create transformation cassette
2. Introduce and select for transformants
Transformation Cassettes
-
8/2/2019 Biopharming Training
93/97
Transformation Cassettes
Contains
1. Gene of interest
The coding region and its controlling elements
2. Selectable marker
Distinguishes transformed/untransformed plants
3. Insertion sequencesAidsAgrobacterium insertion
Transformation Steps
-
8/2/2019 Biopharming Training
94/97
Transformation Steps
Prepare tissue for transformation
Introduce DNA
Culture plant tissueDevelop shoots
Root the shoots
Field test the plants
Leaf, germinating seed, immature embryos
Tissue must be capable of developing into normal plants
Agrobacterium or gene gun
Multiple sites, multiple years
D li i th G
-
8/2/2019 Biopharming Training
95/97
Transformation cassettes are developed in the lab
They are then introduced into a plant
Two major delivery methods
Delivering the Gene
to the Plant
Agrobacterium
Gene GunTissue culturerequired to generate
transgenic plants
-
8/2/2019 Biopharming Training
96/97
The Lab Steps
-
8/2/2019 Biopharming Training
97/97
The Next Test Is The Field
Non-transgenics
Transgenics
Herbicide Resistance